Photo detail

CytRx Chief Executive Steven Kriegsman

Stories this photo appears in:

CytRx Licenses Cancer Drug to NantCell; Asks Shareholders for Reverse Stock Split

Brentwood-based CytRx Corp. will team up with Patrick Soon-Shiong’s NantCell Inc. of Culver City to test a late-stage cancer drug, CytRx announced Thursday. The company also asked investors Tuesday to approve a one-for-six reverse stock split to continue the company’s listing on the Nasdaq exchange, according to Securities and Exchange Commission filings.

Tease photo